Professor Woll leads the Sheffield Experimental Cancer Medicine Centre (ECMC) and is the research lead for the North Trent Cancer Network lung and sarcoma groups.

She has extensive experience of clinical trials testing of new treatments and is a member of national and international collaborative groups, including National Cancer Research Institute (NCRI) and European Organisation for Research and Treatment of Cancer (EORTC) clinical trials groups. 

Penella was chair of the NCRI Clinical Studies Group for sarcoma from 2009 to 2015. 

Dr Booth is an Honorary Consultant, Associate Lecturer at the University of Cambridge; and Honorary Senior Lecturer at the Department of Palliative Care and Policy at King’s College, London.

She has a longstanding interest in breathlessness derived from her first Palliative Care post at St Christopher’s Hospice in London and founded the Breathlessness Intervention Service at Addenbrooke Hopsital. 

During her NHS R&D training fellowship, Sara validated the shuttle walking test for patients with advanced cancer.

Her current research interest focuses on the use of mindfulness as part of symptom control in breathlessness and other chronic conditions.

Dr Brennan is a specialist in Paediatric Oncology and Clinical Trials. 

At the National Cancer Research Initiative (NCRI), Bernadette is a member of the Sarcoma Clinical Studies Group and chairs the Young Onset Soft-tissue Sarcoma (YOSS) subgroup. She is a member of the Children's Cancer and Leukaemia Group (CCLG) Rare Tumour Group and EXPeRT European Rare Tumour Group.

She is clinical lead on the European paediatric Soft tissue sarcoma Study Group (EpSSG) non-rhabdyomyosarcoma soft tissue sarcomas (NRSTS) study for the UK and International/UK Euro Ewing 2012 Study and a member of the Euro Ewing Consortium.

Professor Sue Burchill is the Professor of Adolescent and Paediatric Cancer Research at the University of Leeds. In 1992 she established the Children’s Cancer Research Group in Leeds, where she remains the scientific director.

Sue has made major contributions to medical research in the fields of childhood and adolescent cancer, her leadership in multi-disciplinary collaborative groups includes shaping international strategies on the evaluation of circulating biomarkers.  She is chair of current molecular monitoring biological studies in the European Ewing’s Consortium (EEC) and Society of Paediatric Oncology European Neuroblastoma Group (SIOPEN) run clinical trials.

Her own research is focussed on metastatic drug resistant disease that is responsible for progression and relapse, and using a comprehensive range of preclinical models is investigating novel strategies to detect and eradicate this disease to improve outcomes for young people with Ewing’s sarcoma and neuroblastoma.

Mr Paul Cool is a specialist in Trauma & Orthopaedics and Musculoskeletal Oncology. 

Paul's research interests include orthopaedic oncology; primary bone tumours (benign and malignant); sarcomas (soft tissue and bone); metastatic bone tumours, and tumour-like conditions.

Mr Anant Desai started surgical training in Birmingham and was awarded a Doctorate in Medicine for research into the molecular biology of oesophageal and gastric cancer. 

In 2011, he was appointed Consultant General Surgeon at Queen Elizabeth Hospital Birmingham with an interest in abdominal and retroperitoneal sarcoma.

Anant has had fellowships in the field of sarcoma surgery in Paris at the Institut Gustave Roussy, and Milan at the Istituto Nazionale dei Tumori. He is part of the editorial board for the European Journal of Surgical Oncology, advising on sarcoma and bone tumours. 

Dr Sinclair Dundas is Consultant Pathologist at Aberdeen Royal Infirmary specialising in sarcoma and Honorary Clinical Senior lecturer at the University of Aberdeen.

Sinclair is the Research Lead for the Scottish Sarcoma Network.

Professor of Musculoskeletal Pathology at UCL's Cancer Institute and clinical lead for the diagnostic pathology service for the London Sarcoma Service, Prof. Flanagan specialises in cellular and molecular pathology of bone and soft tissue tumours and non-neoplastic musculoskeletal disorders. 

Additionally, Adrienne is the Meeting Secretary of the Pathological Society of Great Britain and Ireland; Trustee of the Jean Shanks Foundation and the Skeletal Cancer Action Trust (SCAT); a member of the Chordoma Foundation (USA) Scientific Advisory board and co-lead of the International Cancer Genome Consortium bone tumour project.

In 2017, Professor Flanagan was awarded an OBE for services to cancer research.

Prof. Hupp is Principal Investigator and Professor of Cancer Research at the University of Edinburgh. 

Ted's research looks at the tumour suppressor protein p53 and its role in cancer progression. His work looks at how insights into cancer progression pathways, particularly sarcomas, can identify therapeutic strategies.

Dr Messiou is a radiologist at the Royal Marsden Hospital with a specialist interest in imaging soft tissue sarcoma, myeloma and melanoma.

In 2014 she was awarded a Roentgen Professorship by the Royal College of Radiologists and became a member of the Royal College of Radiologists Academic Committee. She is a member of the NCRI Expert Advisory Panel and Steering Committee member of the EORTC Soft Tissue and Bone Sarcoma Group.

Her research interests are focused on directing imaging for patient benefit including whole body MRI, use of machine learning to translate sophisticated tumour analysis into clinical practice and defining tumour heterogeneity to guide therapy.

Professor Shipley’s research is focused on identifying molecular markers of high-risk in young onset sarcomas and understanding associated molecular mechanisms in order to derive novel treatments for these patients. She leads the Sarcoma Molecular Pathology Team at the Institute of Cancer Research. 

She is a member of the of the National Cancer Research Institute (NCRI) Clinical Studies Young Onset Sarcoma Subgroup (YOSS); and is Chair of the Biological Committee for the European paediatric Soft tissue sarcoma Study Group (EpSSG).

She has authored more than 160 peer-reviewed papers.

Dr Karen Sisley is a senior lecturer at the Department of Oncology, University of Sheffield with an interest in rare tumours and specialises in sarcomas. 

Her research focuses on the genetic changes related to subtypes of rare tumours, and the impact that these have on tumour behaviour.

Prof. Spicer is Consultant in Medical Oncology at Guy’s and St Thomas’ Hospitals, and Reader at King’s College London. 

James set up and runs the Cancer Early Phase Trials programme at Guy’s and St Thomas’, and is clinical lead in the Clinical Research Facility at Guy’s Hospital. 

He co-leads the King’s Experimental Cancer Medicine Centre.

He holds a PhD in Cancer Biology from the Institute of Cancer Research in London, and a degree in biochemistry from the University of Oxford. 

Dr Strauss is part of the oncology team for the London Sarcoma Service and specialises in the systemic treatment of bone and soft tissue sarcomas in both adults and teenagers.

Her research focuses on identifying new targets for therapy in osteosarcoma and Ewing's sarcoma and developing early phase clinical trials. She is the principal investigator for a number of clinical trials and is a member of the National Cancer Research Institute Clinical Studies Group for sarcoma and bone subgroup as well as the EORTC Soft Tissue and Bone Sarcoma Group.

Dr Vargesson is Senior Lecturer at the Institute of Medical Sciences, University of Aberdeen with a research interest in how the limbs of the body form and grow out from the sides of the embryo.

His sarcoma research focuses on the role of YAP protein in rhabdomyosarcoma. 

Prof. Velikova leads the Patient Centred Outcomes Group at the Leeds Institute for Cancer and Pathology. She is also a Consultant Oncologist. 

Her research focuses on Quality of Life and she leads the quality of life sub-studies of large national and international research trials in breast cancer. She has worked on the development of a web-based electronic system for collecting patient-reported data on toxicity and adverse events during cancer treatment, integrating this with electronic patient records and generating alerts for clinicians.

She is past chair the British Psychosocial Oncology Society (BPOS) and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group. She is president elect of the International Society for Quality of Life Research.

Dr Wood is Consultant in Palliative Medicine at the Royal Marsden and Royal Brompton Hospitals. She is Clinical Lead for education in the department and also the Training Programme Director for core medical trainees based across the Royal Marsden.

Her interests include pain, symptom control, education and training and medical ethics.